Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

Inclusion Criteria: * Between 18 and 65 years of age, inclusive. * Have a minimal weight of 110 lbs and a body mass index (BMI) between 17 and 35. * In good health. * For pre-menopausal female subjects, using acceptable methods of birth control. * Willing and capable of complying with all aspects of the protocol through completion of the program period. * No blood donation in the preceding 8 weeks; willing to not donate whole blood or plasma during the clinical trial; and willing to not donate whole blood or plasma for up to one year following the last infusion. * Has read and signed an informed consent form. * Adequate venous access and can receive intravenous infusion. Exclusion Criteria: * Previously intolerant of immune globulin or blood product preparations or known immunodeficiency. * Previous treatment with immune globulin products or blood products within three months of study. * Previous receipt of anthrax vaccine, known exposure to anthrax organisms, or previously enlisted in the military. * Receipt of any live vaccine within three months or inactivated vaccine within 2 weeks prior to study; plans to receive any vaccine at any time during the study. * Participation in any investigational clinical trial within one month prior to study. * Positive serology for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus. * Receipt of chemotherapy, radiation therapy, immunosuppressive therapy, or high-dose corticosteroid therapy within five years of study. * Use of prohibited medications as defined in the protocol. * History of drug or alcohol abuse within 1 year of study. * History of IgA deficiency. * Pregnancy. * Positive Coombs test at screening. * Males with a hemoglobin value less than 13.2 gm/dL and females less than 10.9 gm/dL. * Absolute eosinophil counts greater than 600 cells/mm3 or Absolute lymphocyte counts less than 1000 cells/mm3. * Aspartate aminotransferase (AST) \>55 U/L or alanine aminotransferase (ALT) \>60 U/L. * Hyperglycemia with random blood glucose \>141 mg/dL, fasting blood glucose \>112 mg/dL, or urine glucose \>50 mg/dL; or hypoglycemia with a blood glucose \<65 mg/dL. * BUN \>25 mg/dL or creatinine, for males \>1.4 mg/dL and, for females \>1.2 mg/dL. * Creatinine clearance \<80 mL/min. * Urine protein \>15 mg/dL for males and non-menstruating females, or \>30 mg/dL for menstruating females. * Febrile illness within three days prior to infusion. * History of significant medical or psychiatric condition or abnormal laboratory tests indicating possible underlying medical condition. * An opinion of the investigator that a condition exists that would preclude compliance with protocol-specified procedures. * Absolute neutrophil count is less than 3000 cells/mm3 as defined by the central lab (screening) or local lab (pre-infusion) for cohort B. Absolute neutrophil count is less than 2500 cells/mm3 as defined by the central lab (screening) or local lab (pre-infusion) for cohort C. * White blood cell counts are less than 3500 cells/mm3 as defined by the central lab (screening) or local lab (pre-infusion) for cohorts B and C. * History of a severe or anaphylactic reaction to quinolone or penicillin antibiotics.